TrialSignal transduction and targeted therapy2026
A multicohort, biomarker-driven phase 2 trial of personalized total neoadjuvant therapy with targeted agents for high-risk rectal cancer (The TRAINER study).
Tao Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.